Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
|Articles|November 26, 2012
New, Higher Hurdle to Deduct Care
Advertisement
The squeeze is on for folks who rely on the tax code for relief from big medical bills. Starting next year, taxpayers will only be able to deduct medical expenses that exceed 10% of their adjusted gross income.
For years that threshold has stood at an already formidable 7.5% of income. (People age 65 and older can keep using the old threshold through 2016.) The change affects taxpayers who itemize deductions on Schedule A of the 1040 form instead of taking the standard deduction.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
5